...
首页> 外文期刊>The journal of immunology >Topical Glucocorticoid Therapy Directly Induces Up-Regulation of Functional CXCR4 on Primed T Lymphocytes in the Aqueous Humor of Patients with Uveitis
【24h】

Topical Glucocorticoid Therapy Directly Induces Up-Regulation of Functional CXCR4 on Primed T Lymphocytes in the Aqueous Humor of Patients with Uveitis

机译:局部糖皮质激素治疗直接诱导葡萄膜炎患者水液中初生T淋巴细胞功能性CXCR4的上调

获取原文
           

摘要

Overexpression of the constitutive chemokine receptor CXCR4 has been shown to contribute to the accumulation of leukocytes at sites of chronic inflammation. Glucocorticoids are widely used to treat inflammatory disorders such as uveitis to considerable effect, yet paradoxically have been reported to increase CXCR4 expression in vitro. We show here that ocular lymphocytes isolated from patients with uveitis who had been treated with topical glucocorticoids expressed highly elevated levels of CXCR4. The up-regulation of CXCR4 could be reproduced in vitro by culture of CD4+ T cells with aqueous humor (AqH), indicating a role for the ocular microenvironment rather than preferential recruitment of CXCR4+ cells. Untreated uveitis and noninflammatory AqH up-regulated CXCR4 to a limited extent; this was dependent on TGF-β2. However, the highest levels of CXCR4 both in vivo and in vitro were found in the glucocorticoid-treated patients. Glucocorticoids appeared to be directly responsible for the induction of CXCR4 in treated patients, as the glucocorticoid receptor antagonist RU38486 inhibited the in vitro up-regulation by AqH from these patients. Dexamethasone selectively up-regulated CXCR4 in vitro, but not any of a wide range of other chemokine receptors. CXCL12, the ligand for CXCR4, was present in AqH under noninflammatory conditions, but the levels were low in untreated uveitis and undetectable in treated uveitis AqH. The importance of these results for the treatment of HIV patients with glucocorticoids is discussed as well as a role for glucocorticoid-induced CXCR4 up-regulation and CXCL12 down-regulation in controlling the migration of lymphocyte populations, resulting in resolution of inflammation.
机译:组成型趋化因子受体CXCR4的过表达已证明有助于白细胞在慢性炎症部位的积累。糖皮质激素被广泛用于治疗诸如葡萄膜炎之类的炎性疾病,具有显着效果,但矛盾的是,据报道其在体外能增加CXCR4的表达。我们在这里显示,从接受局部糖皮质激素治疗的葡萄膜炎患者分离出的眼部淋巴细胞表达了高度升高的CXCR4。 CXCR4的上调可通过体外培养具有房水(AqH)的CD4 + T细胞来重现,这表明它对眼部微环境起作用,而不是优先招募CXCR4 +细胞。未经治疗的葡萄膜炎和非炎性的AqH在一定程度上上调了CXCR4;这取决于TGF-β2。但是,在接受糖皮质激素治疗的患者体内和体外,CXCR4的含量最高。糖皮质激素似乎直接导致了治疗患者中CXCR4的诱导,因为糖皮质激素受体拮抗剂RU38486抑制了这些患者的AqH体外上调。地塞米松在体外选择性上调CXCR4,但不是其他多种趋化因子受体中的任何一种。 CXCR4(CXCR4的配体)在非炎性条件下存在于AqH中,但在未经治疗的葡萄膜炎中水平较低,而在经过治疗的葡萄膜炎AqH中则检测不到。讨论了这些结果对治疗糖皮质激素的HIV患者的重要性,以及糖皮质激素诱导的CXCR4上调和CXCL12下调在控制淋巴细胞群体迁移中的作用,从而导致炎症消退。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号